Relmada Therapeutics, Inc. today announced that Sergio Traversa , Chief Executive Officer, Maged Shenouda , Chief Financial Officer, and Cedric O’Gorman, Chief Medical Officer, will participate in the 2023 Jefferies Global Healthcare Conference in one-on-one investor meetings and a fireside chat on Thursday, June 8, 2023, at 3:00pm ET in New York, NY.
| CORAL GABLES, Fla., June 2, 2023 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer, Maged Shenouda, Chief Financial Officer, and Cedric O’Gorman, Chief Medical Officer, will participate in the 2023 Jefferies Global Healthcare Conference in one-on-one investor meetings and a fireside chat on Thursday, June 8, 2023, at 3:00pm ET in New York, NY. Please find additional details about the event below.
2023 Jefferies Global Healthcare Conference Relmada management will also be available for one-one-one investor meetings during the conference. Please contact your Jefferies representative if you would like to schedule a meeting. The webcast can be accessed via the Investors section of the Relmada website at https://www.relmada.com/for-investors. An archived replay will be available for 90 days following the conclusion of the event. About REL-1017 REL-1017, a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, is currently in late-stage development for the adjunctive treatment of major depressive disorder (MDD). The ongoing Reliance Clinical Research Program is designed to evaluate the potential for REL-1017 as a rapid-acting, oral, once-daily antidepressant treatment. About Relmada Therapeutics, Inc. Relmada Therapeutics is a late-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Relmada’s experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada’s lead program, REL-1017, is a new chemical entity (NCE) and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Learn more at www.relmada.com. Forward-Looking Statements The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by us or on our behalf. This press release contains statements which constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statement that is not historical in nature is a forward-looking statement and may be identified by the use of words and phrases such as “expects,” “anticipates,” “believes,” “will,” “will likely result,” “will continue,” “plans to,” “potential,” “promising,” and similar expressions. These statements are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those described in the forward-looking statements, including potential failure of Reliance trial results to demonstrate clinically significant evidence of efficacy and/or safety, failure of top-line results to accurately reflect the complete results of the trial, failure to obtain regulatory approval of REL-1017 for the treatment of major depressive disorder, and the other risk factors described under the heading “Risk Factors” set forth in the Company’s reports filed with the SEC from time to time. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. Relmada undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Readers are cautioned that it is not possible to predict or identify all the risks, uncertainties and other factors that may affect future results and that the risks described herein should not be a complete list. Investor Contact: Media Inquiries:
SOURCE Relmada Therapeutics, Inc. | ||
Company Codes: NASDAQ-NMS:RLMD |
View original content to download multimedia:
